Prof. Hillmen on whether CLL is curable today
BTK inhibitors: toxicity, resistance, and combinations
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
The role of TP53 in CLL